Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Position Raised by Caprock Group LLC

Caprock Group LLC grew its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 6.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,698 shares of the specialty pharmaceutical company’s stock after buying an additional 543 shares during the quarter. Caprock Group LLC’s holdings in Collegium Pharmaceutical were worth $249,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after acquiring an additional 175,892 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in shares of Collegium Pharmaceutical in the 3rd quarter valued at $757,000. Barclays PLC lifted its stake in shares of Collegium Pharmaceutical by 152.2% in the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock valued at $2,899,000 after purchasing an additional 45,291 shares during the last quarter. Sanctuary Advisors LLC boosted its holdings in Collegium Pharmaceutical by 10.7% in the third quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock worth $695,000 after purchasing an additional 1,731 shares in the last quarter. Finally, FMR LLC increased its position in Collegium Pharmaceutical by 1,532.2% during the third quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock worth $1,459,000 after buying an additional 35,439 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on COLL shares. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Piper Sandler decreased their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Stock Performance

COLL opened at $30.95 on Friday. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The stock’s 50 day moving average price is $31.03 and its two-hundred day moving average price is $34.14. The firm has a market capitalization of $998.14 million, a P/E ratio of 13.34 and a beta of 0.82. Collegium Pharmaceutical, Inc. has a 12-month low of $28.39 and a 12-month high of $42.29.

Insider Activity

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the company’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the transaction, the executive vice president now directly owns 119,184 shares in the company, valued at $3,937,839.36. This represents a 18.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.98% of the stock is owned by company insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.